Design and development of synthetic peptide vaccines: Past, present and future

Expert Review of Vaccines

Volumn 6, Issue 4, 2007, Pages 591-603

  Bijker, Martijn S ^a   Melief, Cornelis J M ^a   Offringa, Rienk ^a   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Peptide vaccination; Pharmacokinetics; Tolerance; Toll like receptor

Indexed keywords

CD40 ANTIGEN; CPG 7909; ISCOM; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MINERAL OIL; PHOSPHORYL LIPID A; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ADD ON THERAPY; ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INCLUSION; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; PEPTIDES; VACCINES, SYNTHETIC;

EID: 34548035780     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.4.591     Document Type: Review

References (153)

1. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13, 835-837 (1953).
2. Baldwin RW. Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors. Br. J. Cancer 9, 652-665 (1955).
3. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
4. Klein G, Sjogren HO, Klein E, Hellström KE. Demonstration of resistance against mythylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960).
5. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702 (1974).
6. Townsend AR, McMichael AJ, Carter NP, Huddleston JA, Brownlee GG. Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell 39, 13-25 (1984).
7. Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457-467 (1985).
8. Townsend AR, Rothbard J, Gotch FM. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968 (1986). • Shows that cytotoxic T lymphocytes (CTLs) recognized short linear peptide sequences instead of the native protein structure expressed on the cell surface of influenza-infected cells.
9. Falk K, Rotzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348, 248-251 (1990).
10. Rotzschke O, Falk K, Deres K et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252-254 (1990).
11. Rotzschke O, Falk K, Wallny HJ, Faath S, Rammensee HG. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249, 283-287 (1990).
12. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991). •• Illustrates that for good binding to the MHC class I molecule, the peptide has to comply to certain amino acids at fixed positions (anchor residues). Just by using these anchor residues, epitopes could be predicted from many different proteins.
13. Rotzschke O, Falk K, Stevanovic S et al. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21, 2891-2894 (1991).
14. Pamer EG, Harty JT, Bevan MJ. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 353, 852-855 (1991).
15. Calin-Laurens V, Trescol-Biemont MC, Gerlier D, Rabourdin-Combe C Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination? Vaccine 11, 974-978 (1993).
16. Oldstone MB, Lewicki H, Borrow P, Hudrisier D, Gairin JE. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69, 7423-7429 (1995).
17. Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171, 1815-1820 (1990). • The first synthetic peptide vaccine that was able to induce virus-induced CTLs
18. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl Acad. Sci. USA 88, 991-993 (1991). •• One of the first two reports that demonstrate that synthetic peptide vaccines can protect mice against a lethal challenge with live virus.
19. Kast WM, Roux L, Curren J et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl Acad. Sci. USA 88, 2283-2287 (1991). •• Second of the two reports that demonstrate that synthetic peptide vaccines can protect mice against a lethal challenge with live virus.
20. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).
21. + T cells. Proc. Natl Acad. Sci. USA 91, 3171-3175 (1994).
22. Mandelboim O, Vadai E, Fridkin M et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1, 1179-1183 (1995).
23. Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 155, 95-99 (1992).
24. Overwijk WW, Tsung A, Irvine KR et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277-286 (1998).
25. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8, 1014-1018 (2002).
26. Kyburz D, Aichele P, Speiser DE et al. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956-1962 (1993).
27. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182, 261-266 (1995).
28. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702 (1998).
29. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918 (1996). • One of two important papers in which the authors showed that peptide vaccination can result in enhanced tumor outgrowth.
30. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855-7860 (1996). • One of two important papers in which the authors showed that peptide vaccination can result in enhanced tumor outgrowth.
31. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol. 5, 681-689 (2004).
32. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
33. Feltkamp MC, Vierboom MP, Kast WM, Melief CJ. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol. Immunol. 31, 1391-1401 (1994).
34. Sette A, Vitiello A, B Reherman et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
35. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180, 1471-1483 (1994).
36. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156, 3308-3314 (1996).
37. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL iin vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160, 1750-1758 (1998).
38. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. 51, 614-620 (2002).
39. Tang Y, Lin Z, Ni B et al. An altered peptide ligand for naive cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer Immunol. Immunother. 56, 319-329 (2007).
40. Dyall R, Bowne WB, Weber LW et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553-1561 (1998).
41. Vierboom MP, Feltkamp MC, Neisig A et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J. Immunother. 21, 399-408 (1998).
42. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 88, 1635-1644 (1996).
43. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327 (1998).
44. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 59, 301-306 (1999).
45. Wang F, Ono T, Kalergis AM et al. On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor beta chain. Proc. Natl Acad. Sci. USA 95, 5217-5222 (1998).
46. + cytotoxic lymphocyte population. J. Immunol. 162, 7263-7270 (1999).
47. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
48. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768-782 (1982).
49. + T cells via CD40-CD40L interactions or, alternatively, by the use of an agonistic CD40 antibody.
50. + T cells via CD40-CD40L interactions or, alternatively, by the use of an agonistic CD40 antibody.
51. + T cells via CD40-CD40L interactions or, alternatively, by the use of an agonistic CD40 antibody.
52. + T lymphocytes. Nature 421, 852-856 (2003).
53. + T cells, was shown to strongly reduce the peptide induced CTL response.
54. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
55. Scheibenbogen C, Schadendorf D, Bechrakis NE et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer 104, 188-194 (2003).
56. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556 (1994).
57. Hiranuma K, Tamaki S, Nishimura Y et al. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80(Pt 1), 187-193 (1999).
58. Slingluff CL Jr, Yamshchikov G, Neese P et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7, 3012-3024 (2001).
59. Del VM, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66, 1145-1153 (1991).
60. Gileadi U, Gallimore A, BP van der, Cerundolo V. Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. Eur. J. Immunol. 29, 2213-2222 (1999).
61. Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl Acad. Sci. USA 88, 5887-5891 (1991).
62. +) T cell responses in humans. Proc. Natl Acad. Sci. USA 101, 10697-10702 (2004).
63. Ayyoub M, Merlo A, Hesdorffer CS et al. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin. Immunol. 114, 70-78 (2005).
64. Bioley G, Jandus C, Tuyaerts S et al. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J. Immunol. 177, 6769-6779 (2006).
65. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484 (2001).
66. Valmori D, Romero JF, Men Y et al. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur. J. Immunol. 24, 1458-1462 (1994).
67. Casares N, Lasarte JJ, de Cerio AL et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 31, 1780-1789 (2001).
68. +) T helper cells. J. Virol. 75, 10593-10602 (2001).
69. Steinaa L, Rasmussen PB, Wegener AM et al. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J. Immunol. 175, 329-334 (2005).
70. + T-cell repertoire. Cancer Res. 65, 6443-6449 (2005).
71. Diehl L, AT den Boer, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774-779 (1999).
72. -) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl Acad. Sci. USA 99, 5561-5566 (2002).
73. + CTL to cause tumor eradication. J. Immunol. 173, 6753-6759 (2004).
74. den Boer AT, Diehl L, van Mierlo GJ et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 167, 2522-2528 (2001). • Demonstrates that the use of incomplete Freund's adjuvant in combination with minimal CTL peptide vaccination results in long-term antigen presentation leading to T-cell tolerance.
75. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002). • Demonstrates that extending the minimal MHC class I peptide induces a more robust CTL response capable of eradicating established tumors.
76. van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev. 58, 916-930 (2006).
77. Kast WM, Brandt RM, Melief CJ. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur. J. Immunol. 23, 1189-1192 (1993).
78. Gao XM, Zheng B, Liew FY, Brett S, Tite J. Priming of influenza virus-specific cytotoxic T lymphocytes in vivo by short synthetic peptides. J. Immunol. 147, 3268-3273 (1991).
79. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54, 4155-4161 (1994).
80. Reinholdsson-Ljunggren G, Ramqvist T, Ahrlund-Richter L, Dalianis T. Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens. Int. J. Cancer 50, 142-146 (1992).
81. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001).
82. Jensen FC, Savary JR, Diveley JP, Chang JC. Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug Deliv. Rev. 32, 173-186 (1998).
83. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457-460 (1984).
84. Sjolander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 19, 2661-2665 (2001).
85. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat. Rev. Immunol. 4, 512-520 (2004).
86. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199, 775-784 (2004).
87. Welters MJ, Bijker MS, van den Eeden SJ et al. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25, 1379-1389 (2007).
88. Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA 89, 358-362 (1992).
89. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005).
90. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561-564 (1989). • First usage of a peptide vaccine coupled to a lipopeptide (tripalmitoyl-S-glycerylcysteinyl-seryl-serine), which was shown to efficiently prime influenza virus-specific CTL in vivo.
91. Maurer T, Heit A, Hochrein H et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32, 2356-2364 (2002).
92. Khan S, Bijker MS, Weterings JJ et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145-21159 (2007).
93. Jackson DC, Lau YF, Le T et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101, 15440-15445 (2004).
94. Borges E, Wiesmuller KH, Jung G, Walden P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Methods 173, 253-263 (1994).
95. Heit A, Schmitz F, O'Keeffe M et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174, 4373-4380 (2005).
96. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776 (2005).
97. Warger T, Osterloh P, Rechtsteiner Get al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108, 544-550 (2006).
98. Sutmuller RP, MH den Brok, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116, 485-494 (2006).
99. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175, 5601-5605 (2005).
100. Weijzen S, Meredith SC, Velders MP et al. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J. Immunol. 166, 7151-7157 (2001).
101. +) T cells. J. Exp. Med. 188, 1977-1983 (1998).
102. Suhrbier A, Burrows SR, Fernan A et al. Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J. Immunol. 150, 2169-2178 (1993).
103. + cytotoxic T lymphocytes is due to fratricide. J. Immunol. 151, 658-667 (1993).
104. Diehl L, AT den Boer, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy. Nat. Med. 5, 774-779 (1999).
105. Yamshchikov GV, Mullins DW, Chang CC et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174, 6863-6871 (2005).
106. Lehmann F, Marchand M, Hainaut P et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25, 340-347 (1995).
107. Vambutas A, DeVoti J, Nouri M et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23, 5271-5280 (2005).
108. +) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31, 1989-1998 (2001).
109. Perlaza BL, Sauzet JP, Balde AT et al. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur. J. Immunol. 31, 2200-2209 (2001).
110. + T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 23, 2801-2812 (2005).
111. Audran R, Cachat M, Lurati F et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73, 8017-8026 (2005).
112. Mata E, Carcaboso AM, Hernandez RM et al. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 25, 877-885 (2007).
113. Welters MJ, Filippov DV, van den Eeden SJ et al. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 23, 305-311 (2004).
114. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. 11, 1474-1482 (2005).
115. Andersen MH, Svane IM, Kvistborg P et al. Immunogenicity of Bcl-2 in patients with cancer. Blood 105, 728-734 (2005).
116. Andersen MH, Reker S, Kvistborg P, Becker JC, thor SP. Spontaneous immunity against Bcl-xL in cancer patients. J. Immunol. 175, 2709-2714 (2005).
117. Andersen MH, Becker JC, thor SP. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 19, 484-485 (2005).
118. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679 (1999).
119. + T cell responses against TRAG-3 in patients with melanoma and breast cancers. J. Immunol. 177, 2717-2727 (2006).
120. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis. Tumor Immunol. 18, 86-94 (1995).
121. Heit A, Maurer T, Hochrein H et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170, 2802-2805 (2003).
122. Romano F, Cesana G, Caprotti R et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology 53, 634-638 (2006).
123. Picker LJ, EF Reed-Inderbitzin, Hagen SI et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest. 116, 1514-1524 (2006).
124. Klebanoff CA, Finkelstein SE, Surman DR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101, 1969-1974 (2004).
125. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006). •• Reports that the use of IL-2 cytokines complexed to antibodies not only enhanced the in vivo efficacy dramatically of this cytokine, it also greatly reduced the cytotoxicity.
126. Rubinstein MP, Kovar M, Purton JF et al. Converting IL-15 to a superagonist by binding to soluble IL-15Rα Proc. Natl Acad. Sci. USA 103, 9166-9171 (2006).
127. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177, 6072-6080 (2006).
128. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
129. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107, 628-636 (2006).
130. + regulatory T-cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA (2007) (Epub ahead of print).
131. + subset. Cancer Res. 47, 3317-3321 (1987).
132. Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother. Biol. Response Modif. 20, 301-313 (2002).
133. Dannull J, Su Z, D Rizzieri et al. Enhancement of vaccine-mediated antitumor Immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005).
134. Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor Immunity. J. Immunol. 164, 2160-2169 (2000).
135. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6, 528-536 (2002).
136. Diehl L, GJ van Mierlo, den Boer AT et al. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J. Immunol. 168, 3755-3762 (2002).
137. + T cells in patients with melanoma. J. Immunol. 175, 6169-6176 (2005).
138. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996). •• Illustrates the in vivo use of blocking antibodies against the negative T-cell regulation cytotoxic T-lymphocyte antigen (CTLA)-4, resulted in the rejection of tumors including pre-established tumors. The data shows that blockade of CTLA-4 can be a promising adjuvant strategy in anticancer vaccines.
139. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
140. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227 (2006).
141. + T cells. J. Exp. Med. 204(4), 879-891 (2007)
142. Gajewski TF, Meng Y, Blank C et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
143. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
144. Prinz BM, Hafner J, Dummer R et al. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients. Transplantation 77, 790-791 (2004).
145. Waeckerle-Men Y, AE Uetz-von, Fopp M et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55, 1524-1533 (2006).
146. Lee P, Wang F, Kuniyoshi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847 (2001).
147. Valmori D, Dutoit V, Ayyoub M et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3, 15 (2003).
148. Lefrancois L, Marzo A, Williams K. Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo. J. Immunol. 171, 2832-2839 (2003).
149. Stock AT, Mueller SN, AL van Lint, Heath WR, Carbone FR. Cutting edge: prolonged antigen presentation after herpes simplex virus-1 skin infection. J. Immunol. 173, 2241-2244 (2004).
150. Bins AD, Jorritsma A, Wolkers MC et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11, 899-904 (2005).
151. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601 (2005).
152. Ashton-Rickardt PG. A license to remember. Nat. Immunol. 5, 1097-1098 (2004).
153. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5, 1289-1297 (1999).